Transcriptome profiling revealed that E2 (33.3 μg/infusion) lead to down-regulation of insulin growth factor 1 (IGF1), a cytokine that has been suggested to promote cancer survival and tumor metastasis [86,87]. This evidence concerns the gene IGF1 and neoplasm.